Phase 2 Study of Selinexor in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents: Interim Report. (April 2017) - Klimek, V.M.; Coleman, M.; Alvarez, K.; Sen, F.; Pichardo, J.; Kashyap, T.; Klebanov, B.